Trial ID or NCT#

NCT00242619

Status

not recruiting iconNOT RECRUITING

Purpose

Insulin resistance is known to be associated with mood disorders and cognitive difficulties. The purpose of this study is to treat depressed patients with rosiglitazone (also known as [AKA] Avandia), therefore improving glucose sensitivity, which in turn has the potential to affect mood and thinking. We, the researchers at Stanford University, are recruiting men and women who have been diagnosed with depression, and are willing to participate in this 3 month study. Participation involves neuropsychological testing, 2 blood draws called an oral glucose tolerance test (OGTT), which tests for glucose and insulin levels, and the medication, rosiglitazone. Participants are allowed to continue on their current psychiatric medication.

Official Title

Rosiglitazone Add-On in Treatment of Depressed Patients With Insulin Resistance: a Pilot Study

Eligibility Criteria

Ages Eligible for Study: 18 Years to 60 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Natalie L. Rasgon
Natalie L. Rasgon
Psychiatrist
Professor of Psychiatry and Behavioral Sciences (General Psychiatry and Psychology-Adult) at the Stanford University Medical Center, Emerita

Contact us to find out if this trial is right for you.

CONTACT

SPECTRUM